Your browser doesn't support javascript.
loading
Adherence to Long-Term Follow-Up of Patients with Life-Threatening, Inhaled Synthetic Cannabinoids-Associated Coagulopathy in Chicago.
Tole, Mateo; LaBedz, Stephanie; Feinstein, Douglas L; Rubinstein, Israel.
Afiliação
  • Tole M; Division of Pulmonary, Critical Care, Sleep and Allergy Medicine, Department of Medicine (M/C 719), University of Illinois at Chicago, 840 South Wood Street, Chicago, IL, 60612, USA.
  • LaBedz S; Medical Service, Jesse Brown VA Medical Center, Chicago, IL, 60612, USA.
  • Feinstein DL; Division of Pulmonary, Critical Care, Sleep and Allergy Medicine, Department of Medicine (M/C 719), University of Illinois at Chicago, 840 South Wood Street, Chicago, IL, 60612, USA.
  • Rubinstein I; Medical Service, Jesse Brown VA Medical Center, Chicago, IL, 60612, USA.
Lung ; 197(3): 349-352, 2019 06.
Article em En | MEDLINE | ID: mdl-31004190
ABSTRACT
A large-scale outbreak of life-threatening, inhaled synthetic cannabinoids (Spice/K2)-associated coagulopathy with bleeding complications was recently reported in Illinois. The causative agents were brodifacoum, difenacoum, and bromadiolone, potent, long-acting, 4-hydroxycoumarin anticoagulant rodenticides (LAAR) that were mixed with Spice/K2 products procured and then inhaled by the victims. We report on 3 poisoned patients who reside in underserved, socioeconomically disadvantaged neighborhoods of Chicago that were admitted and treated successfully at two inner-city, tertiary care hospitals in Chicago. The patients were discharged from the hospitals on daily long-term high-dose oral vitamin K1 (VK1), provided free of charge. However, 2 patients were lost to follow-up prior to safe discontinuation of oral VK1 therapy. The third patient was treated and followed successfully for 7 months when VK1 was discontinued. We conclude that prolonged oral VK1 therapy and follow-up of acute, life-threatening LAAR poisoning are variable and present challenges to healthcare providers. Appropriate practice guidelines to improve patient access and adherence to daily high-dose oral VK1 therapy and follow-up should be developed and implemented.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vitamina K 1 / Transtornos da Coagulação Sanguínea / Canabinoides / Cooperação do Paciente / Hemorragia / Anticoagulantes / Antifibrinolíticos Tipo de estudo: Guideline / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vitamina K 1 / Transtornos da Coagulação Sanguínea / Canabinoides / Cooperação do Paciente / Hemorragia / Anticoagulantes / Antifibrinolíticos Tipo de estudo: Guideline / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article